MYR
Key Facts
| Invested since | 2011 |
| Based in | Burgwedel |
About the company
MYR, acquired by Gilead Sciences in 2021, developed a peptide-based, first-in-class drug to combat chronic hepatitis delta. The drug has been approved by the EMA for the treatment of chronic hepatitis delta in Europe and is in preparation for approval by the US FDA.
Do you want to
know more about this company?
MYR in the news
zum Artikel
Most Successful Exit in the History of High-Tech Gründerfonds – Gilead Sciences to Acquire MYR GmbH
More startups from Life Sciences
Treatment of sustainable plaque in coronary arteries through our proprietary catheter based device.
to Cryotherapeutics
Symphera is a Munich-based startup that is revolutionizing laparoscopic surgery with an innovative system designed to eliminate the need for manual instrument changes. Founded in 2023, Symphera was incubated at …
to Symphera
Draupnir Bio is a spin out company, from Aarhus University and the Max-Planck Society and establishing itself at the forefront of protein degradation. Draupnir’s novel and proprietary platform technology is …
to Draupnir Bio
Ebenbuild is a health tech pioneer that creates personalized treatment recommendations for mechanical ventilation and ICU patient care for clinical users. Founded in Munich in 2019, the company develops software …
to Ebenbuild
WMT developes small molecules for cancer indications by targeting the Warburg Metabolism. The Warburg Metabolism was first described 100 years ago by Otto Heinrich Warburg and the therapeutic approach is …
to WMT
The company was founded in 2022 and is headquartered at the STIMULATE research campus in Magdeburg’s “science-harbour”. The scientific company is a spin-off by scientists from the Otto-von-Guericke-University Magdeburg. The …
to RAYDIAX
Exit
Provecs Medical develops novel products from its platform technology for cancer treatment by specific activation of the immune system. Exit since July 2015.
to Provecs Medical
Exit
GME German Medical Engineering develops and markets a new generation of laser and lightsystems (small, light weight, modular) for the use in cosmetic and medical dermatology.
to GME
Dimericon is a private biotech company focused on exploring the novel modality crosslinked helix dimers (Dimericons) to target hard-to-drug intracellular protein-protein interactions using rationally designed mimetics of helix dimers. The …
to Dimericon
PreComb Therapeutics AG is a privately held Swiss biotech company founded in 2018 by Jens M. Kelm, Peter Steiner and Olivier Mauti with the aim of developing technologies that bring …
to PreComb
WISE Srl is a Milan and Berlin-based company developing genuinely novel and minimally-invasive implantable leads for Neuromodulation and Neuromonitoring: highly conformable, stretchable, unbreakable and cheaper to produce.
to WISE
Optimization of atrial fibrillation therapy via precise, non-thermal pulsed field ablation
to Argá Medtech